Amgen Pays $71M In Multistate Drug-Marketing Settlement
Law360, New York (August 18, 2015, 1:06 PM EDT) -- Amgen Inc. agreed Tuesday to a $71 million settlement with 48 state attorneys general who accused the drugmaker of marketing its anemia drug Aranesp and plaque psoriasis drug Enbrel, both biologic medications, for uses beyond the scope of the U.S. Food and Drug Administration's approval.
(Credit: AP) The Thousand Oaks, California-based drugmaker agreed to a consent judgment Tuesday with New York Attorney General Eric Schneiderman and others after they claimed it marketed Aranesp for cancer-related anemia without FDA approval and promoted Enbrel to treat mild plaque psoriasis — an auto-immune problem that causes the flaking and scaling of skin cells —...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!